Inside Innovation

In a $43 billion deal, Pfizer will acquire Bothell-based biotech Seagen, expected to be completed in late 2023 or early 2024. Pfizer intends to maintain

CBRE’s recent report for Q4 2022 shows promise for the future of Seattle’s life science industry. The region recorded its highest fourth-quarter capital funding on

Moderna wants to tap Seattle’s pool of talent, the Cambridge, Massachusetts-based company announced last week. It is opening an office on April 4 with plans

At the 2023 UW Medical Data Science Symposium the University of Washington launched a new hub named the Institute for Medical Data Science. The new

In a dynamic interview with Osmosis Raise the Line podcast, Marc Cummings, president & CEO of Life Science Washington, and Dr. Tina Albertson, chief medical officer

A new report from CBRE shows that the life sciences real estate market began to normalize in the fourth quarter, with rebounding numbers in venture

Seattle-based biotech Monod Bio has licensed a new luciferase technology (LuxSit), which is a de novo enzyme luciferase technology. The technology comes from the lab

Newsweek and global research and data firm Statista announced the fourth-annual ranking of the 500 most responsible companies regarding ESG (environment, social and corporate governance)

In KPMG’s 2023 Healthcare and Life Sciences Investment Outlook, eight industries and subsectors were analyzed by macroeconomic and geopolitical upheaval and how deal activity and

The STEM workforce, expected to grow 11% by 2031 according to the US Department of Labor, is an area of continual advancement, vital for future

While the life science real estate market may be slowing to some, life science experts believe it is still strong and stabilizing itself after vacancies

Dr. Nora Disis, director of the Cancer Vaccine Institute at UW Medicine and a University of Washington and Fred Hutch Cancer Center faculty member, is close to a breakthrough breast cancer